Holen Sie sich die Stockscreener-App
2.15
4.44%
-0.10
Handel nachbörslich:
2.23
0.08
+3.72%
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com Australia
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan
Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider
Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR - Stock Titan
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com India
[144] FATE THERAPEUTICS INC SEC Filing - Stock Titan
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - TradingView
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential By Investing.com - Investing.com South Africa
Jefferies Initiates Fate Therapeutics(FATE.US) With Buy Rating, Announces Target Price $4 - Moomoo
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $2.25 - Moomoo
Fate Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Fate Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Key Disclosures - Minichart
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
FT819 Remodels Lupus B Cells in Clinical Trial - CRISPR Medicine News
Fate Therapeutics Reports Q1 2026 Financial Results, Advances FT819 and FT839 CAR T-Cell Trials with Extended Cash Runway into 2028 - Minichart
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics (NASDAQ: FATE) narrows Q1 2026 loss as R&D costs fall - Stock Titan
Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary - TradingView
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028 - TradingView
Fate Therapeutics: Q1 Earnings Snapshot - KTVB
Fate Therapeutics reports Q1 2026 net loss $31.2M, cash and investments $174.8M; runway into 2028 - TradingView
Fate Therapeutics (NASDAQ: FATE) trims Q1 loss, extends cash runway and advances FT819 - Stock Titan
Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 (NASDAQ:FATE) - Seeking Alpha
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
Fate Therapeutics presents CAR T-cell therapy data at ASGCT - Investing.com UK
Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com - Investing.com South Africa
Fate Therapeutics Showcases FT819 Clinical Activity in SLE - GlobeNewswire
Fate Therapeutics (FATE) Eps Diluted (TTM) - Zacks Investment Research
Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
MSN Money - MSN
FATE Technical Analysis | Trend, Signals & Chart Patterns | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics Inc (FATE) Stock Price Today & Analysis - Gotrade
Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares - Stock Titan
Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates - Stocktwits
Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake - Stock Titan
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
HC Wainwright Issues Positive Estimate for FATE Earnings - MarketBeat
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com India
Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com
Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - The Manila Times
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):